FDA — authorised 3 August 2012
- Application: BLA125418
- Marketing authorisation holder: SANOFI AVENTIS US
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 Vegf Trap in United States
FDA authorised Vegf Trap on 3 August 2012
Marketing authorisations
FDA — authorised 6 October 2014
- Application: BLA125387
- Marketing authorisation holder: REGENERON PHARMACEUTICALS
- Indication: Efficacy
- Status: approved
FDA — authorised 23 August 2024
- Application: BLA761298
- Marketing authorisation holder: AMGEN INC
- Status: approved
FDA — authorised 17 April 2025
- Application: BLA761378
- Marketing authorisation holder: FORMYCON AG
- Indication: Supplement
- Status: approved
The FDA approved Vegf Trap, a product of Formycon AG, for the indication of supplement on 2025-04-17. This approval was granted through a standard expedited pathway. The application number for this approval is BLA761378.
FDA — authorised 19 November 2025
- Application: BLA761355
- Marketing authorisation holder: REGENERON PHARMACEUTICALS
- Indication: Efficacy
- Status: approved
Regeneron Pharmaceuticals received marketing authorisation from the FDA for Vegf Trap on 19 November 2025. The application number for this approval is BLA761355. Vegf Trap was approved through the standard expedited pathway. The approved indication for Vegf Trap is for its efficacy.
Vegf Trap in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Vegf Trap approved in United States?
Yes. FDA authorised it on 3 August 2012; FDA authorised it on 6 October 2014; FDA authorised it on 23 August 2024.
Who is the marketing authorisation holder for Vegf Trap in United States?
SANOFI AVENTIS US holds the US marketing authorisation.